Dupixent® (dupilumab) late-breaking phase 3 data presented at ueg week 2022 showed significant histological remission of eosinophilic esophagitis (eoe) in children 1 to 11 years old

A majority of children on dupixent (up to 68% on a higher dose) achieved histological disease remission at week 16 first and only phase 3 trial to show positive results in this patient population; there are currently no approved treatments specifically indicated for children under 12 years of age with eoe tarrytown, n.y. and paris , oct. 11, 2022 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) and sanofi today presented late-breaking positive results from a phase 3 trial evaluating the investigational use of dupixent® (dupilumab) in children aged 1 to 11 years with active eosinophilic esophagitis (eoe).
REGN Ratings Summary
REGN Quant Ranking